Results from the German etravirine early access programme

A. Stoehr, H.-J. Stellbrink, S. Marks, H. Vanaken, C. Vogt, A. Hill & TMC125-C214 Study Group
Background: The next generation NNRTI etravirine (ETR, TMC125) has shown strong and durable efficacy in the DUET trials (combined with darunavir/ritonavir, NRTIs and optional enfuvirtide). Methods: The TMC125-C214 trial (etravirine early access programme) included patients with triple class[for full text, please go to the a.m. URL]